Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy

Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4 (0327), 141–142.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
MARC-2
2012
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012.

J Clin Oncol 30(suppl 5; abstr 467). doi: 10.1200/jco.2012.30.5_suppl.467

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: GCS (ASCO) / Journal: Journal of Clinical Oncology
MARC-2
2012
Mutation analysis from the REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV.

Schirmacher, P., Schuette, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Zaun, S., Dietel, M., 2012.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGP / Journal: -
REASON
2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases–a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski, C.C., Mohler, M., Schon, M., van Cutsem, E., Greil, R., Bechstein, W.O., Hegewisch-Becker, S., von Wichert, G., Vohringer, M., Heike, M., Heinemann, V., Peeters, M., Kanzler, S., Kasper, S., Overkamp, F., Samonigg, H., Seehofer, D., Kullmann, F., Schmidtmann, I., Smith-Machnow, V., Gockel, I., Lang, H., Galle, P.R., 2012.

BMC Cancer 12, 144. doi:10.1186/1471-2407-12-144

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: BMC Cancer
LICC
2012
A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Schimanski, C.C., Moehler, M.H., Lang, H., Schoen, M., Smith-Machnow, V., Kanzler, S., Hegewisch-Becker, S., Doerfel, S., Seehofer, D., Bechstein, W., Heike, M., Overkamp, F., Kullmann, F., Voehringer, M., Heinemann, V., von Wichert, G., Kasper, S., Greil, R., Samonigg, H., Galle, P.R., 2012.

J Clin Oncol 30 (suppl 15; Abstract 99605). doi: 10.1200/jco.2012.30.15_suppl.tps3641

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
LICC
2012
Sequential systemic treatments of patients with metastatic renal cell carcinoma in German oncology and onco-urology outpatient centers. Data from the clinical RCC Registry.

Müller, L., Goebell, P., Harich, H., Vogt, M., Marschner, N., 2012.

Onkologie 35 (suppl 6)(V684), 203. doi:10.1159/000178474

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Onkologie
TNK
2012
Behandlungsrealität in Deutschland: Daten aus dem Klinischen Tumorregister Mammakarzinom.

Marschner, N., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
TMK
2012
Effectiveness of taxane- or anthracylin-based compared to taxane- and anthracyline-free 1st-line treatments in metastatic breast cancer patients in German oncology outpatient centres. Data from the clinical TMK Registry.

Marschner, N., Tesch, H., Dörfel, S., Meyer, D., Petersen, V., Jänicke, M., 2012.

Onkologie 35 (suppl 6)(P223), 68. doi:10.1159/000170919

Abstract

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Onkologie
TMK
2012
Umsetzung von Leitlinien in der klinischen Praxis. Was können wir aus Klinischen Tumorregistern lernen?

Marschner, N., Kopfmann, S., 2012.

FORUM 27, 465–468.

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Forum
Registerübergreifend
2012
Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres.

Knauf, W.U., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012.

Blood 120(21), 3666.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASH / Journal: Blood
TLN
2012